About us

BlueGnome was founded in in 2002 by a team of scientists who developed a novel mathematical technology for the analysis of genetic data following the sequencing of the human genome in 2000. Over the following 10 years BlueGnome has seen rapid growth and adoption of its technology and has become a leading provider of genetic solutions for the screening of chromosomal abnormalities in cytogenetics and IVF. In September 2012 BlueGnome was acquired by Illumina and is now a wholly owned subsidiary of Illumina - enhancing the company’s ability to establish integrated solutions in reproductive health and cancer. Below is a timeline of BlueGnome's milestones to date.

BlueGnome Brochure Preview
View a larger version of this image


With the support of the University of Cambridge and the Wellcome Trust, BlueGnome went on to assemble a world class team of mathematicians, biologists and software engineers with the aim of developing a range of genetic tests which used these advances to improve human health.

In February 2006 BlueGnome released the CytoChip, a powerful new genetic test for the investigation of genetic abnormalities. The CytoChip is now used in over 40 countries world wide. Since 2006 over 100,000 samples have been investigated using the CytoChip, mainly associated with developmental delay or with complex leukaemias. The CytoChip is now used in over 200 labs as a first line cytogenetic test, replacing traditional G-band karyotyping.

In 2008 BlueGnome applied its unique combination of technology and expertise to the problem of counting the chromosomes in a single human cell.  In collaboration with some of the world’s leading IVF centres, BlueGnome developed 24sure and in September 2009 the first 24sure baby, Oliver, was born in the UK. 24sure is well positioned to revolutionize the world of IVF, with recent studies showing dramatic improvements to IVF birth rates and corresponding reductions in miscarriage rates. 24sure has the potential to become the defacto standard of care for IVF cycles worldwide and BlueGnome is working to make that vision into a reality.

BlueGnome is privately held, profitable and has been included in the Deloitte Fast 50 for the third year running, recently ranked the 2nd fastest growing biotech company in the UK with over 85% of sales going for export to major laboratories around the world. BlueGnome is now proud to have been awarded the Queen’s Award for Enterprise in International Trade.

In 2012 BlueGnome was acquired by Illumina, a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function, BlueGnome is now a wholly owned subsidiary of Illumina.

Our news items can be found here